Payment overview · 2025
General Payments
$720.97
37 reported records · 13 companies
Healthcare provider profile · identity verified
Taufik Kassis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRENCHBURG, KY · NPI 1174545628
Verified facts
What the public records show
CMS Open Payments records show Taufik Kassis, MD received $720.97 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $191.56 | 26.6% | 10 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $85.72 | 11.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.49 | 9.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.82 | 8.8% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.34 | 8.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $57.26 | 7.9% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $54.76 | 7.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.63 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.35 | 3.9% | 2 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.89 | 2.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.30 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.96 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.89 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $720.97 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $132.96 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $65.49 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.82 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $63.34 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $54.76 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.07 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.28 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.63 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 97 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 129 |
| Lisinopril | Lisinopril | 335 | 84 |
| Gabapentin | Gabapentin | 297 | 49 |
| Potassium Chloride | Potassium Chloride | 287 | 60 |
| Omeprazole | Omeprazole | 284 | 69 |
| Furosemide | Furosemide | 258 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 57 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 211 | 22 |
| Losartan Potassium | Losartan Potassium | 209 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 62 |
| Trazodone Hcl | Trazodone Hcl | 191 | 42 |
| Metformin Hcl | Metformin Hcl | 167 | 38 |
| Ozempic | Semaglutide | 161 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 43 |
| Eliquis | Apixaban | 154 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 40 |
| Sertraline Hcl | Sertraline Hcl | 147 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 121 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 14 |
| Montelukast Sodium | Montelukast Sodium | 99 | 25 |
| Carvedilol | Carvedilol | 98 | 22 |
| Mirtazapine | Mirtazapine | 97 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 29 |
| Metformin Hcl Er | Metformin Hcl | 96 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 23 |
| Famotidine | Famotidine | 87 | 19 |
| Jardiance | Empagliflozin | 86 | 20 |
| Farxiga | Dapagliflozin Propanediol | 82 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 22 |
| Ezetimibe | Ezetimibe | 73 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 14 |
| Alendronate Sodium | Alendronate Sodium | 66 | 11 |
| Pregabalin | Pregabalin | 65 | suppressed |
| Nifedipine Er | Nifedipine | 62 | 22 |
| Finasteride | Finasteride | 58 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 14 |
| Ondansetron Odt | Ondansetron | 56 | 15 |
| Bumetanide | Bumetanide | 55 | 11 |
| Mounjaro | Tirzepatide | 54 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 11 |
| Glipizide | Glipizide | 50 | 13 |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 50 | 16 |
| Atenolol | Atenolol | 49 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 49 | 13 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 18 |
| Simvastatin | Simvastatin | 47 | 15 |
| Buspirone Hcl | Buspirone Hcl | 46 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 18 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Allopurinol | Allopurinol | 40 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 11 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 11 |
| Baclofen | Baclofen | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Prednisone | Prednisone | 31 | 20 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 14 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 14 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Repaglinide | Repaglinide | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $720.97 · 37 records | ABBVIE INC. | BRIXADI, CAPLYTA, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Fabhalta, JARDIANCE, LEQVIO, MAVYRET, MOUNJARO, QULIPTA, REBYOTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error